Rep. Kevin Hern Sells Exact Sciences Corporation (NASDAQ:EXAS) Stock

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Exact Sciences Corporation (NASDAQ:EXAS). In a filing disclosed on April 03rd, the Representative disclosed that they had sold between $1,001 and $15,000 in Exact Sciences stock on March 24th. The trade occurred in the Representative’s “GABRIELLE ASHTYN HERN TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $50,001 – $100,000 in shares of Prologis (NYSE:PLD) on 3/20/2026.
• Sold $15,001 – $50,000 in shares of T. Rowe Price Group (NASDAQ:TROW) on 3/20/2026.
• Sold $15,001 – $50,000 in shares of Medtronic (NYSE:MDT) on 3/20/2026.
• Sold $500,001 – $1,000,000 in shares of Smartstop Self Storage REIT (NYSE:SMA) on 3/18/2026.
• Sold $500,001 – $1,000,000 in shares of Texas Instruments (NASDAQ:TXN) on 3/18/2026.
• Sold $50,001 – $100,000 in shares of BlackRock MuniAssets Fund (NYSE:MUA) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Cognizant Technology Solutions (NASDAQ:CTSH) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Invesco (NYSE:IVZ) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Becton, Dickinson and Company (NYSE:BDX) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Comcast (NASDAQ:CMCSA) on 3/17/2026.

Exact Sciences Stock Performance

EXAS opened at $104.91 on Tuesday. The company has a current ratio of 2.43, a quick ratio of 2.17 and a debt-to-equity ratio of 0.97. The stock has a market capitalization of $20.03 billion, a PE ratio of -95.37, a PEG ratio of 2.02 and a beta of 1.41. Exact Sciences Corporation has a 1-year low of $38.81 and a 1-year high of $104.98. The firm has a 50-day moving average price of $103.62 and a two-hundred day moving average price of $90.07.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Friday, February 13th. The medical research company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.29). The company had revenue of $878.38 million during the quarter, compared to analyst estimates of $860.59 million. Exact Sciences had a negative net margin of 6.40% and a positive return on equity of 0.53%. The company’s revenue was up 23.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.06) EPS. As a group, equities analysts anticipate that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Marshall Wace LLP boosted its stake in Exact Sciences by 1,553.1% during the 2nd quarter. Marshall Wace LLP now owns 429,719 shares of the medical research company’s stock worth $22,835,000 after acquiring an additional 403,724 shares during the last quarter. Holocene Advisors LP boosted its stake in Exact Sciences by 189.5% during the 2nd quarter. Holocene Advisors LP now owns 2,145,181 shares of the medical research company’s stock worth $113,995,000 after acquiring an additional 1,404,086 shares during the last quarter. Fisher Asset Management LLC boosted its stake in Exact Sciences by 25.5% during the 3rd quarter. Fisher Asset Management LLC now owns 198,287 shares of the medical research company’s stock worth $10,848,000 after acquiring an additional 40,258 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in Exact Sciences during the 4th quarter worth approximately $47,848,000. Finally, Sumitomo Mitsui Trust Group Inc. boosted its stake in Exact Sciences by 643.1% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,286,595 shares of the medical research company’s stock worth $70,390,000 after acquiring an additional 1,113,459 shares during the last quarter. Institutional investors own 88.82% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on EXAS shares. Mizuho reaffirmed a “neutral” rating and issued a $105.00 target price (up from $85.00) on shares of Exact Sciences in a research note on Tuesday, January 20th. Zacks Research lowered shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Evercore set a $105.00 target price on shares of Exact Sciences and gave the company an “in-line” rating in a research note on Monday, January 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Exact Sciences in a research note on Thursday, January 22nd. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Exact Sciences in a research note on Tuesday, March 24th. Twenty-one research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Exact Sciences has an average rating of “Reduce” and an average target price of $92.13.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Exact Sciences

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.